Annual Congress Vienna 2009

Saturday, 12.09.2009
Sunday, 13.09.2009
Monday, 14.09.2009
Tuesday, 15.09.2009
Wednesday, 16.09.2009

Citations should be made in the following way: Authors. Title. Eur Respir J 2009; 34: Suppl. 53, abstract number.

Material from 2009:

4047 Abstracts
652 Slide presentations
300 Webcasts
93 Handouts
2150 e-posters
300 Multimedia files

Material from 2009: Show

New bronchodilators

Thematic Poster Session
Chairs: R. Buhl (Mainz, Germany), R. Sakalauskas (Kaunas, Lithuania)

Download all media

A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a b₂ adrenoreceptor agonist, PF-00610355 J. Ward, F. Macintyre, I. Jones, B. Surujbally (Sandwich, United Kingdom)
Safety and toleration of pf-00610355, a novel inhaled long acting β₂ adrenoreceptor agonist G. L. Li, F. MacIntyre, B. Surujbally, C. L. Chong, J. Davis (Sandwich, United Kingdom; Singapore, Singapore)
Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study H. Magnussen, P. Paggiaro, D. Jack, R. Owen, M. Higgins, B. Kramer (Grosshansdorf, Germany; Pisa, Italy; Horsham, United Kingdom; East Hanover, United States Of America)
Effects of intratracheal pf-00610355, an inhaled β₂ adrenoceptor agonist, in anaesthetised animals L. Sladen, K. Wright, J. Adcock, P. Chaffe, N. Clarke, M. Yeadon, C. Perros-Huguet (Sandwich, United Kingdom)
Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling J. Ribbing, G. L. Li, E. Van Schaick, L. Harnisch (Sandwich, United Kingdom; Mechelen, Belgium)
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD P. Jones, A. Agusti, P. Chanez, H. Magnussen, L. Fabbri, J. Maroni, E. Garcia Gil (London, United Kingdom; Mallorca, Barcelona, Spain; Marseille, France; Grosshansdorf, Germany; Modena, Italy; New Jersey, United States Of America)
Investigation of the enzymatic hydrolysis of aclidinium bromide in human plasma J. Albertí, A. Martinet, S. Sentellas, M. Salvà (Barcelona, Spain)
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) V. Nonikov, C. Verkindre, D. Jack, P. Bleasdale, R. Owen, B. Kramer, M. Higgins (Moscow, Russian Federation; Beuvry, France; Horsham, United Kingdom; East Hanover, United States Of America)
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium C. Fogarty, J. Hebert, A. Iqbal, R. Owen, M. Higgins, B. Kramer (Spartanburg, East Hanover, United States Of America; Quebec, Canada; Horsham, United Kingdom)
Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study R. Buhl, W. Pieters, D. Jack, R. Owen, B. Kramer, M. Higgins (Mainz, Germany; Helmond, Netherlands; Horsham, United Kingdom; East Hanover, United States Of America)
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD L. M. Fabbri, B. Van de Maele, B. Lemmens, C. Martin, R. Horton, M. Dolker, T. Overend (Modena, Italy; Oostende, Belgium; Amboise Cedex, France; Horsham, United Kingdom; East Hanover, United States Of America)
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium A. Yorgancioglu, D. Mahler, A. Iqbal, R. Owen, M. Higgins, B. Kramer (Manisa, Turkey; New Hampshire, East Hanover, United States Of America; Horsham, United Kingdom)
*Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus* placebo and tiotropium** J. Lötvall, B. G. Cosio, A. Iqbal, J. Swales, R. Owen, B. Kramer, M. Higgins (Göteborg, Sweden; Palma de Mallorca, Spain; Horsham, United Kingdom; East Hanover, United States Of America)
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study H. Worth, E. Kleerup, A. Iqbal, R. Owen, B. Kramer, M. Higgins (Fuerth, Germany; Los Angeles, East Hanover, United States Of America; Horsham, United Kingdom)
Cardiac safety of indacaterol – no clinical effect on qt in healthy subjects S. Khindri, R. Sabo, S. Harris, S. Jennings, A. F. Drollman (West Sussex, United Kingdom; East Hanover, Miami, United States Of America)
Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses M. Aubier, R. Buhl, T. Ekstrom, J. Haughney, J. Ostinelli, C. P. van Schayck, O. Selroos (Paris, Rueil Malmaison, France; Mainz, Germany; Sodertalje, Angelholm, Sweden; Aberdeen, United Kingdom; Maastricht, Netherlands)
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD H. K. Yum, I. N. Park, S. B. Choi, H. K. Kim, H. Jung, J. W. Hur, H. K. Lee, S. S. Lee, H. P. Lee, S. J. Choi (Seoul, Busan, Ilsan, Republic Of Korea)
Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide G. Lahu, N. Nassr, R. Herzog, M. Elmlinger, P. Ruth, A. Huennemeyer (Konstanz, Tübingen, Germany)